Leap Therapeutics rise on colorectal cancer study enrollment milestone

Cypherpunk Technologies

12/04/2023 13:28

** Shares of cancer drug developer Leap Therapeutics Inc
 LPTX.O  rise 4.6% to $0.31 premarket
    ** Completes patient enrollment in the initial part of
mid-stage study for drug to treat colon, rectal and anal cancers
    ** Initial part has 33 patients enrolled and is designed to
expand into a 130-patient trial in later phase
    ** Initial data expected in mid-2023 
    ** Stock down 33.33% YTD

 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))